Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avacta Group plc ( (GB:AVCT) ) just unveiled an announcement.
Avacta Group plc has announced the appointment of David Bryant and Richard Hughes as Non-Executive Directors, enhancing its board with their extensive experience in pharmaceuticals and capital markets. This strategic move supports Avacta’s transformation into a dedicated therapeutics company, leveraging its preCISION® platform to advance its innovative pipeline and build long-term shareholder value.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company that focuses on developing advanced cancer therapies using its proprietary preCISION® platform. This platform is designed to deliver potent anti-tumor agents directly to tumors, minimizing damage to healthy tissues and optimizing patient outcomes. Avacta’s innovative pipeline includes peptide drug conjugates and Affimer® drug conjugates, which offer distinct advantages over traditional therapies.
Average Trading Volume: 1,921,572
Technical Sentiment Signal: Sell
Current Market Cap: £106.3M
For a thorough assessment of AVCT stock, go to TipRanks’ Stock Analysis page.